SCHEMBL16440971

SCHEMBL16440971

CCC/C(=N/C(C)(C)C)c1ccc2ccn(C)c2c1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
KDM2B Q8NHM5 1/20 0.36
HDAC3 O15379 1/20 0.35
HDAC1 Q13547 1/20 0.35
MAPK11 Q15759 1/20 0.34
MAPK14 Q16539 1/20 0.34
CHRNA7 P36544 1/20 0.34
GPR183 P32249 1/20 0.33
MTNR1A P48039 1/20 0.32
MTNR1B P49286 1/20 0.32
RIPK1 Q13546 1/20 0.31
KDM4E B2RXH2 2/20 0.31
HPGD P15428 2/20 0.31
LMNA P02545 1/20 0.31
MAPT P10636 1/20 0.31
HTT P42858 1/20 0.31
GFER P55789 1/20 0.31
PER2 O15055 1/20 0.31
CRY1 Q16526 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745723 1.00 CYP2A6 (0.37) CYP2A6L3MBTL1KDM2BHDAC3HDAC1
SCHEMBL14745755 1.00 CYP2A6 (0.37) CYP2A6L3MBTL1KDM2BHDAC3HDAC1
SCHEMBL14744681 0.89 MAOB (0.40) CYP2A6HDAC3HDAC1CHRNA7KDM4E
SCHEMBL14744680 0.89 MAOB (0.40) CYP2A6HDAC3HDAC1CHRNA7KDM4E
SCHEMBL16440982 0.79 PLG (0.43) MTNR1AMTNR1BKDM4EHPGDLMNA
SCHEMBL14745056 0.77 TUBB4A (0.44) MTNR1AMTNR1B
SCHEMBL16440973 0.77 TUBB4A (0.44) MTNR1AMTNR1B
SCHEMBL14745057 0.77 TUBB4A (0.44) MTNR1AMTNR1B
SCHEMBL14745378 0.76 APP (0.33) CHRNA7
SCHEMBL14745379 0.76 APP (0.33) CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP CYP2A6 3494/4885L3MBTL1 321/4885KDM2B 4212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.